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A simple, sensitive and rapid liquid chromatographic method was developed and validated for the anal-
ysis of ﬂunixin meglumine (ﬂunixin-M) in bulk, pharmaceutical dosage forms, bovine liver and kidney.
Analytical separation was performed in less than 4 min using a C18 column with UV detection at
284 nm. A micellar solution composed of 0.15 M sodium dodecyl sulphate, 8% n-butanol and 0.3% trieth-
ylamine in 0.02 M phosphoric acid buffered at pH 7.0 was used as the mobile phase. The method was fully
validated in accordance with the International Conference on Harmonization (ICH) guidelines. The limit
of detection and the limit of quantitation were 0.02 and 0.06 lg mL1, respectively. The recoveries
obtained were in range of 95.58–106.94% for bovine liver and kidney. High extraction efﬁciency was
obtained without matrix interference in the extraction process and in the subsequent chromatographic
determination. The method showed good repeatability, linearity and sensitivity according to the evalua-
tion of the validation parameters.
 2015 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Flunixin, 2-[[2-methyl-3-(triﬂuoro-methyl) phenyl] amino]-3-
pyridine carboxylic acid (Fig. 1) [1], is usually found as its
meglumine salt. Its actions are related to its ability to inhibit cyclo-
oxygenase. It is used in horses for the alleviation of inﬂammation,
pain associated with musculoskeletal disorders and visceral pain
associated with colic. In cattle, it is indicated for the control of pyr-
exia associated with bovine respiratory diseases, endotoxemia and
acute bovine mastitis [2]. Flunixin was the second leading violative
residue reported in 2007, so the FDA Center for Veterinary Medi-
cine (FDA-CVM) warned veterinarians to use ﬂunixin in the proper
and labeled manner. The FDA-CVM states that using a different
route of administration for convenience is not adequate reason
for extra label use, making most intramuscular or subcutaneous
use of ﬂunixin illegal. Given intravenous, the label withdrawal time
is 4 days and the milk withdrawal is 36 h. Given intramuscular or
subcutaneous the withdrawal time may be more in order of
40 days [3]. Flunixin has no Codex maximum residual limits
(MRLs) approved for use at national level for food animals anddeﬁnitive MRLs have been established for use in veterinary medic-
inal products in the EC (European Commission) (Annex I of Regula-
tion, No. 2377/90), in bovine liver 300 lg/kg and in the kidney
100 lg/kg [4].
Various methods have been reported for the determination of
ﬂunixin-M including electrochemical [5], gas chromatography
[6–8], thin layer chromatography [9], spectrophotometric [10].
Few liquid chromatographic (LC) methods have been reported for
its determination. It was determined in swine muscles and pro-
cessed food using tandem mass spectrometric detection [11,12],
also in horse urine, mutton muscle, pharmaceutical dosage forms
and bovine plasma using UV detection [9,13–15].
Micellar liquid chromatography (MLC) allows complex matrices
to be analyzed without the need of extraction and with direct
injection of the samples [16]. Micelles tend to bind proteins com-
petitively, thereby releasing protein-bound drugs and proteins,
rather than precipitating into the column. Proteins are solubilized
and washed harmlessly away, eluting with the solvent front. This
means that costs and analysis times are cut considerably [17].
Micellar mobile phases usually need less quantity of organic mod-
iﬁer and generate less amount of toxic waste in comparison to
aqueous–organic solvents, so that they are less toxic, non-inﬂam-
mable, biodegradable and relatively inexpensive [18]. MLC has
proved to be a useful technique in the determination of diverse
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samples [25–28].
The aim of the present study was to develop simple, rapid, sen-
sitive, selective and relatively inexpensive LC method for analysis
of ﬂunixin-M in bulk, dosage forms and in bovine liver and kidney
with a simple and rapid sample preparation especially for the rou-
tine analysis.
2. Experimental
2.1. Materials
Pure ﬂunixin-M sample was kindly supplied by Delta Pharma,
Cairo, Egypt. Its purity was of 99.9% as stated by the supplier. Fluni-
dyne injections, B.N. 0846/11, each mL is labeled to contain 83 mg
ﬂunixin-M equivalent to 50 mg ﬂunixin, a product of Arab com-
pany for medical products, Egypt, purchased from local market.
Bovine liver and kidney were purchased from the local market.
2.2. Reagents and chemicals
All reagents and solvents used were of HPLC grade. High purity
water was used throughout the study.
Ortho-phosphoric acid (85%, w:v), 1-propanol and n-butanol
were obtained from Sigma–Aldrich (Germany). Methanol and ace-
tonitrile were obtained from Fisher Scientiﬁc (UK). Sodium dodecyl
sulphate (SDS) was obtained from Oxford Laboratory, Mumbai
(India). Triethylamine was obtained from SD-Fine-Chem. limited
(India). Nylon ﬁlters and syringe ﬁlters were from Sartorius–Stedi-
um (Goettingen, Germany).
2.3. Instrumentation
Chromatographic analysis was carried out using a Shimadzu
Prominence HPLC system, (Shimadzu, Japan) with a LC-20 AD
pump, DGU-20 A5 degasser, CBM-20A interface, and SPD-20A
UV–Vis detector with 20 lL injection loop. Centrifugation was car-
ried out using a TDL-60 B Centrifuge (Anke, Taiwan). Ultrasonic
bath used was BHA-180 T (Abbotta, USA) was used. Tissue homog-
enization was made using Tissue Master-125 with 7-mm stainless
steel generator probe (Omni International, GA, USA). The pH was
measured with Jenway pH meter, 4510, (Essex-UK). The mobile
phase was ﬁltered through Charles Austen Pumps Ltd. Filter,
model-B100 SE (England, UK) using 0.45 lm milli-pore ﬁlters
(Gelman, Germany).
2.4. Chromatographic conditions
MLC was performed on Shim-Pack VP-ODS column
(150 mm  4.6 mm i.d., 5 lm particle size) Shimadzu, Japan using
micellar mobile phase consisting of 0.15 M sodium dodecyl sul-
phate, 8% n-butanol and 0.3% triethylamine in 0.02 M ortho-phos-
phoric acid buffered at pH 7.0. The mobile phase was ﬁltered and
sonicated for 30 min before use. The ﬂow rate was 1.0 mL/min
and sample injection volumes were 20 lL at room temperature
(25 C). The UV detector was operated at 284 nm..
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Fig. 1. Chemical structure of ﬂunixin-M.2.5. Standard solutions
Stock solution of 0.2 mg mL1 of ﬂunixin-M was prepared by
dissolving 10 mg ﬂunixin-M in 50 mL of water then the solution
was sonicated in an ultrasonic bath for 5 min. Working solutions
were prepared by diluting the stock solution with the mobile
phase. Stock solution was found to be stable for 5 days if stored
in the refrigerator.2.6. Preparation of calibration curves
Working solutions containing (0.1–2.0 lg mL1) and (2.0–
20 lg mL1) of ﬂunixin-M were prepared by serial dilutions of ali-
quots of the stock solution. Then, 20 lL aliquots were injected
(triplicate) and eluted with the mobile phase under the reported
chromatographic conditions. The average peak areas were plotted
versus the concentrations of the drug in lg/mL. Alternatively, the
corresponding regression equations were derived.2.7. Application to injection
Five Flunidyne injections were mixed and an aliquot of the
mixed solution equivalent to 100 mg was transferred to a 100-
mL volumetric ﬂask and completed to volume with water to obtain
a solution claimed to contain 1.0 mg mL1 ﬂunixin-M. 10-mL of the
above solution was diluted to 50 mL with water to obtain a drug
solution claimed to contain 0.2 mg mL1. Solutions were analyzed
following the details under ‘‘Preparation of calibration curves’’.2.8. Bovine liver and kidney samples preparation
2.5 g of the bovine liver or kidney was accurately weighed and
spiked with aliquots of ﬂunixin-M solution. The spiked samples
were homogenized and completed to 25 mL of 0.15 M SDS solution
of pH 7.0. The samples were homogenized at 5000 rpm for 5 min;
then, the homogenate was sonicated for 15 min and then centri-
fuged at 3000 rpm for 5 min. The supernatant of the samples was
ﬁltered through 0.45-lm membrane ﬁlters using vacuum pump.
The ﬁltrate was diluted with the mobile phase, ﬁltered through
syringe ﬁlter. Aliquots of 20 lL were injected (triplicate) and eluted
with the mobile phase under the above chromatographic condi-
tions. The average peak area was plotted versus the concentration
of ﬂunixin-M in lg mL1 to get the calibration curve.3. Results and discussion
The proposed method permits the quantitation of ﬂunixin-M in
bulk, pharmaceutical dosage forms, bovine liver and kidney. The
proposed method offers high sensitivity as low as 0.0196 lg mL1
of ﬂunixin-M could be detected accurately.
Different parameters affecting the chromatographic perfor-
mance of ﬂunixin-M were carefully studied in order to achieve
the most suitable chromatographic system. The results of the opti-
mization study can be summarized as follows:3.1. Choice of appropriate detection wavelength
UV detection was set at different wavelengths depending on the
absorbance properties of the drug (Fig. 2). It was found that,
284 nm is the optimal wavelength to maximize the sensitivity of
determination of the drug.
Fig. 2. Absorption spectrum of intact ﬂunixin-M (20 lg mL1) in distilled water.
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Two different columns were used for performance investiga-
tions, including: Shim-Pack VP-ODS C18 (250 mm  4.6 mm i.d.,
5 lm particle size) and Shim-Pack VP-ODS C18 (150 mm  4.6 mm
i.d., 5 lm particle size).
The experimental studies revealed that the second column was
more suitable, since it produced well-resolved peaks in a reason-
able time.100
150
ea3.3. Mobile phase composition
To achieve the appropriate chromatographic conditions, the
mobile phase composition was optimized to provide sufﬁcient
selectivity and sensitivity in a short separation time. The studied
variables included; the pH of the mobile phase, concentration ofTable 1
Optimization of the chromatographic conditions for the determination of ﬂunixin-M.
Parameter No. of
theoretical
plates (N)
Capacity
factor (K0)
Tailing
factor
(tr)
pH of the mobile
phase
4.0 1100 4.49 1.29
4.5 1080 4.05 1.45
6.0 1010 2.28 1.54
6.5 1199 1.70 1.50
7.0 1294 1.64 1.23
7.5 1220 0.75 1.49
Conc. of SDS (M) 0.075 990 1.21 1.62
0.1 1000 1.98 1.41
0.125 1280 1.81 1.27
0.15 1294 1.64 1.23
0.175 1300 1.361 1.30
Type of organic
modiﬁer of conc.
8% v/v
Butanol 1294 1.61 1.23
Propanol 870 1.20 1.27
Acetonitrile 980 1.33 1.37
Methanol 1100 1.72 2.2
Ethanol 1013 1.98 1.82
% of 1-butanol (% v/
v)
8% 1294 2.0 1.23
10% 1300 1.54 1.20
12% 916 1.35 1.48
Flow rate (mL/min) 0.8 1005 1.71 1.52
1.0 1294 1.64 1.23
1.2 1300 1.61 1.59SDS, the type and concentration of organic modiﬁer and the ﬂow
rate. The results obtained are presented in Table 1.3.4. Effect of pH
The effect of changing the pH of the mobile phase on the selec-
tivity and retention time of ﬂunixin-M was investigated using
mobile phases of pH ranging from 4.0 to 7.5 with 0.15 M SDS con-
centration and 8% n-butanol. Table 1 shows that a pH of 7.0 was
most appropriate, where it offers a good combination of peak sym-
metry and analysis time.0.0 0.5 1.0 1.5 2.0 2.5
0
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Fig. 3. Calibration graph for the HPLC determination of ﬂunixin meglumine by the
proposed method.
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Fig. 4. Calibration graph for the HPLC determination of ﬂunixin meglumine by the
proposed method.
Table 2
Analytical performance data for the HPLC determination of ﬂunixin-M.
Parameter Values
Working range
(0.1–2.0 lg mL1)
Working range
(2.0–20 lg mL1)
Intercept 0.6604 11.39
Slope 49.06 43.66
Correlation coefﬁcient (r) 0.9998 0.9993
SD of residuals (Sy/x) 0.4748 8.564
S.D. of intercept (Sa) 0.292 5.382
S.D. of slope (Sb) 0.3047 0.5102
S.D. 1.201 1.897
% RSD a 1.196 1.901
(LOD) (lg mL1)b 0.02
(LOQ) (lg mL1)c 0.06
a Percentage relative standard deviation.
b Limit of detection.
c Limit of quantitation.
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SDS concentration was varied over the range of 0.075–0.175 M
and containing 8% n-butanol and buffered at pH 7.0. Table 1 shows
that 0.15 M SDS was the best, giving well-resolved peaks and the
highest number of theoretical plates. Retention times increased
when concentration of surfactant decreased.Table 3
Assay results for the determination of ﬂunixin-M in pure form by the proposed and comp
Ranges Proposed method
Amount taken (lg/mL) Amount found (lg/mL) % Recove
0.1–2.0 lg/mL 0.1 0.102 101.19
0.3 0.305 101.76
0.4 0.403 100.81
0.5 0.499 99.97
1.0 0.983 98.31
2.0 2.01 100.34
Mean% ± S.D. 100.39 ±
t-test 1.459
F-test 2.718
2.0–20 lg/mL 2.0 1.979 98.95
3.0 2.949 98.29
4.0 3.939 98.47
5.0 5.12 102.39
10.0 10.211 102.11
15.0 14.671 97.81
20.0 20.136 100.68
Mean% ± S.D. 99.81 ± 1
t-test 1.583
F-test 1.089
Each result is the average of three separate determinations.
The values between parentheses are the tabulated t and F values at P = 0.05.
Table 4
Accuracy and precision data for the determination of ﬂunixin-M by the proposed method
Range Amount taken
(lg/mL)
Intradaya
Amount found ± S.D. (lg/mL) Accuracy (R%) Prec
0.1–2.0 lg/mL 0.1 0.103 ± 0.002 103.00 1.94
0.4 0.405 ± 0.005 101.25 1.23
1.0 1.023 ± 0.011 102.30 1.07
2.0–20 lg/mL 2.0 2.012 ± 0.029 100.60 1.46
10.0 10.235 ± 0.175 102.35 1.71
20.0 20.096 ± 0.169 100.48 0.84
Each result is the average of three separate determinations.
a Within the day.
b Three consecutive days.3.6. Type of organic modiﬁer
The effect of changing the type of organic modiﬁer on the selec-
tivity and retention time of ﬂunixin-M was investigated using
mobile phases containing 8% of either methanol, ethanol, 1-propa-
nol, n-butanol, or acetonitrile and containing 0.15 M SDS and buf-
fered at pH 7.0. Table 1 shows that 8% n-butanol was chosen as the
best organic modiﬁer.3.7. Concentration of organic modiﬁer
The concentration of n-butanol was varied over the range of 8–
12%. Table 1 shows that there is no signiﬁcant difference in the
number of theoretical plates upon using either 8% or 10% n-butanol
so 8% was chosen as it gave well-resolved peaks within a reason-
able retention time. Hence, a small amount of n-butanol is added
to accelerate and control the elution of the drug.3.8. Flow rate
The effect of ﬂow rate of the mobile phase on the retention of
ﬂunixin-M was studied over the range of 0.8–1.2 mL/min. Flow
rate of 1 mL/min was optimal for good separation in a reasonable
time (Table 1).arison methods.
Comparison method
ry Amount taken (lg /mL) Amount found (lg/mL) % Recovery
5.0 5.212 104.20
15.0 15.126 100.84
30.0 30.212 100.71
1.20 101.91 ± 1.98
(2.365)
(19.3)
5.0 5.212 104.20
15.0 15.126 100.84
30.0 30.212 100.71
.897 101.91 ± 1.98
(2.306)
(19.3)
.
Interdayb
ision (RSD%) Amount found ± S.D. (lg/mL) Accuracy (R%) Precision (RSD%)
2 0.102 ± 0.002 102.00 1.961
5 0.407 ± 0.007 101.75 1.72
5 0.997 ± 0.016 99.70 1.605
1 1.997 ± 0.037 99.85 1.843
9.95 ± 0.227 99.50 2.281
1 19.83 ± 0.292 99.15 1.473
Fig. 5. Chromatograms showing (a) ﬂunixin-M standard (10 lg/mL); (b) ﬂunixin-M
(5 lg/mL) in its dosage form; (c) ﬂunixin-M in liver sample (0.5 lg/mL); (d)
ﬂunixin-M in kidney sample (0.5 lg/mL).
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est peak tailing were achieved with well-deﬁned peaks and good
sensitivity within a reasonable analytical run time.
3.9. Method validation
The validity of the proposed method was assessed by studying
the following parameters in accordance to ICH Q2B recommenda-
tions [29]: linearity, LOD, LOQ, accuracy, precision, selectivity,
sample solution stability, mobile phase stability and robustness.
3.10. Linearity
Under the above-described experimental conditions, linear
relationships were established by plotting peak areas against the
drug concentrations (Fig. 3 and 4). The concentration range was
found to be (0.1–2.0 lg mL1) and (2.0–20 lg mL1). Linear regres-
sion analysis of the data gave the following equations:
P ¼ 0:6604þ 49:06C r ¼ 0:9998 ð0:1—2:0 lg=mLÞ
P ¼ 11:39þ 43:66C r ¼ 0:9993 ð2:0—20 lg=mLÞ
where C is the concentration of the drug in lg mL1 and P is the
peak area.
The high value of the correlation coefﬁcient (r value > 0.999)
indicates good linearity of the calibration graph in both cases.
3.11. Limit of quantitation (LOQ) and limit of detection (LOD)
The limit of quantitation (LOQ) was determined by establishing
the lowest concentration of the analyte that can be measured
according to ICH Q2B recommendations [29] and below which
the calibration graph is non-linear and was found to be
0.06 lg mL1. The limit of detection (LOD) was determined by
establishing the minimum level at which the analyte can be reli-
ably detected; it was found to be 0.02 lg mL1 as shown in Table 2.
3.12. Accuracy
To prove the accuracy of the proposedmethod, the results of the
assay of ﬂunixin-M in pure form by the proposed MLC method
were compared with those of the comparison method. The com-
parison method is ﬂunixin-M manufacturer method which
depends on measuring UV-absorbance of the drug at 289 nm in
ethanol.
Statistical analysis of the results obtained using Students’ t-test
and variance ratio F-test [30] revealed no signiﬁcant difference
between the performance of the two methods regarding the accu-
racy and precision, respectively as illustrated in Table 3.
3.13. Precision
Intra-day precision was achieved by determination of three
concentrations of ﬂunixin-M on three successive times in the same
day. Inter-day precision was performed as inter-day precision but
on three successive days. Small values of % RSD revealed the preci-
sion of the proposed method. The results are illustrated in Table 4.
3.14. Selectivity
The selectivity of the proposed MLC method was established by
its ability to determine ﬂunixin-M in commercial injections solu-
tion without interference from any additives, Fig. 5b. Furthermore,
to evaluate the speciﬁcity of the method to determine the cited
drug in bovine liver and kidney, blank samples was prepared and
injected under the recommended chromatographic conditions.No interfering peaks were observed at the retention time of the
drug, which proved the homogeneity and purity of the peak,
Fig. 5c and d.
3.15. Sample solution stability and mobile phase stability
Evaluation of the stability of ﬂunixin-M was achieved by quan-
tiﬁcation of the drug on ﬁve successive days and comparison to
freshly prepared solution. No signiﬁcant changes were observed,
proving that it was stable for up to 5 days. The stability of the
mobile phase was also checked, it was found to be stable for up
to 3 days with no signiﬁcant changes.
3.16. Robustness
To assess the robustness of the proposed MLCmethod, the chro-
matographic conditions were deliberately altered such as pH
(7.0 ± 0.5), concentration of n-butanol (8 ± 0.5%, v/v) and concen-
tration of SDS (0.15 ± 0.025 M). The efﬁciency of the separation of
ﬂunixin-M was not affected indicating the reliability of the pro-
posed method. Therefore, the method is robust to the small
changes in the experimental conditions.4. Applications
4.1. Application of the proposed method to the determination of
ﬂunixin-M in its injection solution
The developed MLC method was applied successfully for the
assay of ﬂunixin-M in Flunidyne injection solution as shown in
Table 5
Assay results for the determination of ﬂunixin-M in injection by the proposed and comparison methods.
Parameters Proposed method Comparison method
Amount taken (lg/mL) Amount found (lg/mL) % Recovery Amount taken (lg /mL) Amount found (lg/mL) % Recovery
Data 2.0 1.956 97.81 5.0 5.04 100.79
3.0 3.025 100.85 15.0 14.917 99.45
4.0 4.08 101.99 30.0 30.009 100.03
5.0 5.027 100.55
10.0 10.097 100.97
15.0 14.538 96.77
20.0 20.263 101.38
Mean% ± S.D. 100.04 ± 1.961 100.09 ± 0.677
t-test 0.04 (2.306)
F-test 8.397 (19.3)
Each result is the average of three separate determinations.
The values between parentheses are the tabulated t and F values at P = 0.05.
Table 6
Assay results for the determination of ﬂunixin-M in bovine liver and kidney by the proposed method.
Method Bovine liver Bovine kidney
Amount taken (lg/mL) Amount found (lg/mL) % Recovery Amount taken (lg/mL) Amount found (lg/mL) % Recovery
Data 0.2 0.214 100.84 0.2 0.211 105.62
0.5 0.478 95.58 0.5 0.482 96.43
1.0 1.008 106.94 1.0 1.007 100.62
Mean 101.12 100.91
S.D. 5.685 4.601
% RSD 5.622 4.56
Each result is the average of three separate determinations.
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of the comparison method using t-test and F-test. The results show
that there were no signiﬁcant differences between the developed
and comparison method regarding accuracy and precision, respec-
tively as illustrated in Table 5.4.2. Application of the proposed method to the determination of
ﬂunixin-M in bovine liver and kidney
The applicability of the procedure developed to determine ﬂun-
ixin-Mwas tested by analyzing the drug in bovine liver and kidney.
All samples were bought at a local Supermarket. Table 6 shows the
results of the analysis of ﬂunixin-M determined in all samples after
homogenization with micellar solution, sonication, centrifugation
and ﬁltration. The data obtained (Table 6) show satisfactory recov-
eries for ﬂunixin-M in all samples, and the results fall in the range
of 95.58–106.94%. Fig. 5 shows the chromatograms obtained from
the spiked samples of ﬂunixin-M analyzed with the optimum
mobile phase.5. Conclusion
The proposed method is useful for food quality testing and con-
trol areas to determine the content of ﬂunixin-M in bovine liver
and kidney samples. One advantage of this procedure is possibility
of injecting the samples directly into the chromatographic system
without previous treatment other than homogenization, dilution
and ﬁltration, thus avoiding tedious extraction from matrices. Val-
idation according to ICH regulations provides satisfactory results in
terms of sensitivity, linearity, accuracy and recoveries. It is note-
worthy that the use of micellar mobile phase endows the proce-
dure advantages such as non-toxicity, non inﬂammability,
biodegradability, and low cost.Conﬂict of interest
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